Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
Month: February 2025
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren Rubin becomes...
White Paper: Polish Presidency of the Council of the European Union 2025. Healthcare Policy Recommendations – A Unique Publication from the Institute for Social Policy Development Now Available
WARSAW, Poland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The White Paper was unveiled on 21 February 2025 at the Medical...
Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights
Physician caring for patient Nurse caring for patient System Architecture February 21, 2025 Integrating advanced data analytics into clinical practice...
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general...
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin,...
Aino Health year-end report January-December 2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating...
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of...
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a...
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
NewGen Issues Clarification on Press Release Titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025
BANGKOK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today issued a clarification...
BioAge Labs to Participate in TD Cowen’s 45th Annual Health Care Conference
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing...
Brighter Strides ABA Expands Services with New Clinic Opening in Maryland
Providing Compassionate, Individualized ABA Therapy for Children with AutismCatonsville, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Brighter Strides ABA is...
AMN Healthcare Announces Fourth Quarter and Full Year 2024 Results
Quarterly revenue of $735 million;GAAP loss of ($4.90)/share and adjusted EPS of $0.75 DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) --...
Globus Medical Reports Fourth Quarter and Full Year 2024 Results
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced...
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
Phoenix Molecular Designs Infographic Introduction to PhoenixMD PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b...
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is...
RaySearch Laboratories: Year-end report 2024
STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2024) Order intake SEK 305.0 M (317.7)Net sales SEK...